Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises
Published Time:
2024-09-09 17:47
Source:
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
The National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises honor is specifically established to encourage small and medium-sized enterprises to achieve development in four aspects: specialized operations, refined output, unique processes, and novel products. It aims to cultivate a group of "pioneer" enterprises focused on niche markets with strong innovation capabilities, high market share, mastery of key core technologies, and excellent quality and efficiency, thereby strengthening the real economy—particularly manufacturing—and enhancing the stability and competitiveness of industrial and supply chains.
Since its establishment, Jiangsu Vcare has been committed to pharmaceutical R&D and innovation, adhering to the "Specialized, Refined, Unique, Innovative" development path, and building a full-chain chemical drug R&D service technology platform. From front-end research, the company has constructed integrated drug R&D platforms including AI molecular generation, drug screening, crystal/salt form selection, and novel drug formulation, establishing core innovation capabilities in early-stage product development. Back-end development further incorporates advanced manufacturing technology platforms such as synthetic biology, enzyme catalysis engineering, and continuous flow engineering, supplemented by preparation/separation technologies and multi-chiral drug development strategies, building robust technical barriers for industrialization. In 2024, the company's revenue will exceed RMB 400 million.
Jiangsu Vcare will continue to uphold its core values of"The better Care, The better Medicines", strengthen its core competitiveness and technological innovation capabilities, and contribute to Chinese pharmaceutical innovation through scientific, conceptual, and management innovation, thereby supporting the "Healthy China" initiative.
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn